In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 4, 2012, Pages 417-419

  He, Wendy ^a   Kaniga, Koné ^a   Lynch, A Simon ^a   Flamm, Robert K ^a,b   Davies, Todd A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

Combination; Doripenem; Etest; Pseudomonas aeruginosa; Synergy

Indexed keywords

AMIKACIN; COLISTIN; DORIPENEM; LEVOFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; EPSILOMETER TEST; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; COLISTIN; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84869090197     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.08.014     Document Type: Article

References (13)

1. Bergen P.J., Tsuji B.T., Bulitta J.B., Forrest A., Jacob J., Sidjabat H.E., et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro PK/PD model. Antimicrob Agents Chemother 2011, 55:5685-5695.
2. Bonapace C.R., White R.L., Friedrich L.V., Bosso J.A. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with E-test, time-kill, and checkerboard methods. Diagn Microbiol Infect Dis 2000, 38:43-50.
3. Chachannidze V., Curbelo-Irizarry A., Ashcraft D., Pankey G. In vitro synergy of levofloxacin plus piperacillin/tazobactam against Pseudomonas aeruginosa. Interdiscip Perspect Infect Dis 2009, 2009:984934. [Internet] Available from:. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774528/.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement (M100-S22) 2012, CLSI, Wayne, PA.
5. Davies T.A., Queenan A.M., Morrow B.J., Shang W., Amsler K., He W., et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011, 66:2298-2307.
6. Garnacho-Montero J., Sa-Borges M., Sole-Violan J., Barcenilla F., Escoresca-Ortega A., Ochoa M., et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35:1888-1895.
7. Hilliard J.J., Fernandez J., Melton J.I., Foleno B., Wira E., Lynch A.S., et al. Activity of doripenem against Pseudomonas aeruginosa alone and in combination with amikacin, colistin, or levofloxacin. Abstr 49th Intersci Conf Antimcrob Agents Chemother 2009, B-1327. (abstr).
8. Kiratisin P., Apisarnthanarak A., Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents 2010, 36:243-246.
9. Lewis R.E., Dickema D.J., Messer S.A., Pfaller M.A., Klepser M.E. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2005, 49:345-351.
10. Pankey G.A., Ashcraft D.S. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005, 49:2959-2964.
11. Pankuch G.A., Seifert H., Appelbaum P.C. Activity of doripenem with and without levofloxacin, amikacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Diagn Microbiol Infect Dis 2010, 67:191-197.
12. Rossolini G.M., Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005, 11(Suppl. 4):17-32.
13. White R.L., Burgess D.S., Manduru M., Bosso J.A. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996, 40:1914-1918.